RTP Mobile Logo
Dermatologic Oncology Update, Issue 1, 2018
Released April 2018

Featuring interviews with Drs Jeffrey Weber, Keith T Flaherty, Adil Daud and Jason J Luke. (Audio Content)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of dermatologic cancers.

    OVERVIEW OF ACTIVITY
    Melanoma and nonmelanoma skin cancers (basal cell carcinoma [BCC] and cutaneous squamous cell cancer [SCC]), taken together, likely represent the most prevalent form of human cancer. The vast majority of skin cancer presents as minimally invasive BCC and SCC and is highly curable with local treatment alone. However, in rare instances these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, malignant melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases, even when identified in the early stages. Thus melanoma and nonmelanoma skin cancers are distinct entities, each posing unique challenges to the oncology community. Featuring up-to-date information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Use biomarkers, clinical characteristics and mutational analyses to select individualized front-line and subsequent treatment approaches for patients with advanced melanoma.
    • Recall available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic BRAF mutation-positive melanoma.
    • Recognize immune-related adverse events associated with immune checkpoint inhibitors, and formulate strategies to minimize and/or manage these side effects.
    • Assess the rationale for and clinical trial data with anti-PD-1/PD-L1 antibodies for patients with Merkel cell carcinoma, and optimally integrate available agents into current treatment algorithms.
    • Formulate a long-term clinical plan for the management of locally advanced or metastatic BCC incorporating existing and investigational treatments.
    • Appraise new data with investigational agents and strategies demonstrating promising activity in melanoma and nonmelanoma skin cancer, and discuss ongoing trial opportunities with eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of each of these CME activities, which includes participation in the evaluation component, enables the participant to earn up to 4.5 (audio) and 5.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/DOU118/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/DOU118/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/DOU118/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/DOU118.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jeffrey Weber, MD, PhD
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    Professor of Medicine
    NYU Langone Medical Center
    New York, New York

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis; Ownership Interest: Altor Bioscience Corp, CytomX Therapeutics; Patents: Biodesix Inc, Moffitt Cancer Center.

    Keith T Flaherty, MD
    Director, Henri and Belinda Termeer Center for Targeted Therapies
    Massachusetts General Hospital Cancer Center
    Professor, Harvard Medical School
    Director of Developmental Therapeutics
    Boston, Massachusetts

    Advisory Committee: Amgen Inc, Sanofi Genzyme, X4 Pharmaceuticals; Board of Directors: Clovis Oncology, Loxo Oncology Inc, Strata Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Novartis, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology; Contracted Research: Novartis, Sanofi Genzyme; Scientific Advisory Board: Adaptimmune, Aeglea BioTherapeutics, Amgen Inc, Apricity Therapeutics, Array BioPharma Inc, Asana BioSciences, Driver, FogPharma, GRAIL, Incyte Corporation, Oncoceutics Inc, Sanofi Genzyme, Scancell, Shattuck Labs, Tolero Pharmaceuticals, Viralytics.

    Adil Daud, MD
    Professor of Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Novartis; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Novartis, OncoSec Medical, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, GlaxoSmithKline, Merck, OncoSec Medical, Pfizer Inc; Ownership Interest: OncoSec Medical.

    Jason J Luke, MD
    Assistant Professor of Medicine
    The University of Chicago
    Chicago, Illinois

    Clinical Trials: AbbVie Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celldex Therapeutics, Corvus Pharmaceuticals, Delcath Systems Inc, Five Prime Therapeutics Inc, Genentech BioOncology, Immunocore, Incyte Corporation, Intensity Therapeutics, MacroGenics Inc, MedImmune Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Tesaro Inc; Consulting Agreements: 7 Hills Pharma LLC, Actym Therapeutics Inc, Amgen Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Benevir Biopharm Inc, Bristol-Myers Squibb Company, Castle Biosciences Incorporated, CheckMate Pharmaceuticals, EMD Serono Inc, Gilead Sciences Inc, Janssen Biotech Inc, Merck, NewLink Genetics, Nimbus Therapeutics, Novartis, Palleon Pharmaceuticals, Syndax Pharmaceuticals Inc, Tempest Therapeutics.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Merck and Novartis.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2018
    Expiration date: April 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Dermatologic Oncology Update, Issue 1, 2018
Released April 2018

Featuring interviews with Drs Jeffrey Weber, Keith T Flaherty, Adil Daud and Jason J Luke. (Audio Content)

Read print: